Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Encorafenib
Brand Name Braftovi®
Payment Category Medicare Part D
Year Introduced 2018
Type of Drug Kinase inhibitor
Manufacturer Array Biopharma
Medical Affairs Questions (date verified) 844.792.7729
Coverage & Reimbursement Questions 866.277.2927

FDA-Approved Indication(s)

  • Indicated, 1) in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and 2) in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. (4/9/20)

Approved Indication(s) with Orphan Drug Status (In combination with binimetinib) Treatment of Stage III-IV melanoma positive for BRAF mutation
ICD-10 Code(s) for Labeled Indication(s) Melanoma [C43.xx]; Colorectal cancer [C18x, C19, C20, or C21.x, dependent on location]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US